Evolocumab 140mg Injection — PCSK9 Inhibitor for Hypercholesterolaemia and Cardiovascular Risk Reduction
Repatha® (Evolocumab) — PCSK9 Inhibitor for Cholesterol Lowering and Cardiovascular Protection
The Most Extensively Studied PCSK9 Inhibitor with Proven Cardiovascular Outcomes Benefit
Repatha® (Evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) — a protein that degrades LDL receptors on liver cells. By blocking PCSK9, Repatha increases the number of LDL receptors available to clear LDL cholesterol from the bloodstream — reducing LDL-C by up to 60% on top of statin therapy and significantly reducing the risk of cardiovascular events including heart attack and stroke.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Repatha (Evolocumab) to hospitals, cardiology centres, lipid clinics, and pharmacies across India. Manufactured by Amgen, Repatha is the most extensively studied PCSK9 inhibitor — with proven cardiovascular outcomes benefit demonstrated in the landmark FOURIER trial.
What is Repatha (Evolocumab)?
Repatha contains Evolocumab — a fully human IgG2 monoclonal antibody that specifically binds to PCSK9 with high affinity. PCSK9 is a serine protease produced primarily in the liver that binds to LDL receptors (LDLR) and directs them for lysosomal degradation — reducing the liver’s capacity to clear LDL cholesterol from the circulation.
By neutralising PCSK9, Repatha prevents LDLR degradation — increasing LDLR recycling to the hepatocyte surface — dramatically increasing hepatic LDL uptake and clearance. This results in significant LDL-C reductions of 50-60% beyond the effect of statin therapy alone.
Full prescribing information is available at the FDA label for Evolocumab.
Clinical Studies and Evidence
FOURIER Trial (Evolocumab Cardiovascular Outcomes) Published in the New England Journal of Medicine (2017), the landmark FOURIER trial — involving 27,564 patients with established cardiovascular disease on statin therapy — demonstrated that Evolocumab significantly reduced the risk of the primary composite cardiovascular endpoint (cardiovascular death, MI, stroke, hospitalisation for unstable angina, or coronary revascularisation) by 15%, and the key secondary endpoint (cardiovascular death, MI, or stroke) by 20%. The trial established Repatha as the first PCSK9 inhibitor with proven cardiovascular outcomes benefit.
GLAGOV Trial (Evolocumab and Atherosclerosis Regression) Published in JAMA (2016), the GLAGOV trial demonstrated that Evolocumab added to statin therapy significantly reduced coronary atherosclerotic plaque volume — with 64.3% of Evolocumab-treated patients showing plaque regression vs 47.3% with placebo — the first evidence that aggressive LDL lowering with a PCSK9 inhibitor can regress atherosclerosis.
PROFICIO Programme (Phase 3 LDL Lowering Trials) The PROFICIO programme — comprising LAPLACE-2, RUTHERFORD-2, GAUSS-3, TESLA, and DESCARTES trials — demonstrated consistent LDL-C reductions of 50-60% with Evolocumab across all patient populations including heterozygous familial hypercholesterolaemia (HeFH), homozygous familial hypercholesterolaemia (HoFH), and statin-intolerant patients.
TESLA Trial (Homozygous FH) Published in The Lancet (2014), the TESLA trial demonstrated Evolocumab significantly reduced LDL-C by 30.9% in patients with homozygous familial hypercholesterolaemia — a condition where statins have limited efficacy.
Long-Term Safety Extension The OSLER extension studies demonstrated sustained LDL-C lowering and a favourable safety profile over 2+ years of continuous Evolocumab treatment — supporting long-term use.
Available Strengths
Repatha is available in the following formulations:
The standard dosing options are:
Indications — What Repatha is Used For
Primary Hyperlipidaemia and Mixed Dyslipidaemia:
Homozygous Familial Hypercholesterolaemia (HoFH):
Established Cardiovascular Disease:
For detailed indication information refer to MedlinePlus Evolocumab.
Key Benefits of Repatha
Proven Cardiovascular Outcomes Benefit The FOURIER trial demonstrated a 15% reduction in primary MACE and 20% reduction in the key secondary endpoint (CV death, MI, stroke) — establishing Repatha as a proven cardiovascular protective therapy beyond LDL lowering alone.
Powerful LDL-C Reduction Repatha reduces LDL-C by 50-60% on top of maximally tolerated statin therapy — enabling patients to achieve very low LDL-C targets (≤55 mg/dL or ≤1.4 mmol/L) as recommended by current guidelines for very high cardiovascular risk patients.
Atherosclerosis Regression The GLAGOV trial demonstrates Repatha can actually regress existing atherosclerotic plaque — going beyond preventing progression to actively reducing plaque burden.
Effective in Familial Hypercholesterolaemia Repatha is effective in both HeFH and HoFH — providing meaningful LDL-C reduction even in HoFH where statins have limited efficacy due to absent or dysfunctional LDL receptors.
Convenient Dosing Options Choice of every-2-week or once-monthly dosing — with multiple device options (syringe, autoinjector, monthly Pushtronex system) — maximising patient convenience and adherence.
Statin-Intolerant Patients Repatha provides meaningful LDL-C reduction in statin-intolerant patients where statins cannot be used at effective doses — addressing a significant unmet clinical need.
How Repatha Works
LDL cholesterol is cleared from the bloodstream primarily by LDL receptors (LDLR) on hepatocytes. After binding LDL, LDLR is internalised and recycled back to the cell surface — ready to bind more LDL molecules. PCSK9 interferes with this recycling process:
Repatha works by:
For a detailed mechanism overview refer to the European Society of Cardiology Dyslipidaemia Guidelines and American College of Cardiology Cholesterol Guidelines.
LDL-C Targets — Current Guidelines
Current ESC/EAS and ACC/AHA guidelines recommend aggressive LDL-C targets for high and very high risk patients:
| Risk Category | LDL-C Target | Common Patients |
|---|---|---|
| Very High Risk | <55 mg/dL (<1.4 mmol/L) | Established CVD, recent ACS, FH with CVD |
| High Risk | <70 mg/dL (<1.8 mmol/L) | Diabetes with organ damage, severe CKD, FH |
| Moderate Risk | <100 mg/dL (<2.6 mmol/L) | Multiple risk factors |
Many patients cannot achieve these targets on statins alone — making Repatha an essential add-on therapy to reach guideline-recommended LDL-C goals.
Repatha vs Sybrava — PCSK9 Inhibition Compared
| Feature | Repatha (Evolocumab) | Sybrava (Inclisiran) |
|---|---|---|
| Mechanism | Anti-PCSK9 monoclonal antibody | siRNA PCSK9 inhibitor |
| LDL-C Reduction | 50-60% | 50-55% |
| Cardiovascular Outcomes | Proven (FOURIER) | Proven (ORION-4) |
| Dosing | Every 2 weeks or monthly | Twice yearly |
| Route | SC injection | SC injection |
| Available at A.K. Pharma | Request Quote | Request Quote |
Dosage and Administration
Primary Hyperlipidaemia / Established CVD:
Homozygous FH:
Administration:
Full dosing guidelines available at Drugs.com Evolocumab Dosage.
Who Should Use Repatha
Repatha is prescribed for:
Repatha is prescribed by cardiologists, lipidologists, endocrinologists, and general physicians. A.K. Pharma supplies Repatha to hospitals, cardiology centres, and pharmacies across Delhi and India.
Possible Side Effects
Common side effects include nasopharyngitis, upper respiratory tract infection, injection site reactions, back pain, and arthralgia.
Serious side effects include:
Full side effect information available at FDA Evolocumab Safety Information.
Precautions
Storage and Handling
As a responsible medicine distributor in Delhi, A.K. Pharma maintains full cold chain requirements during storage and supply of Repatha ensuring product integrity for every unit supplied.
Manufacturer Information
Repatha (Evolocumab) is manufactured by Amgen Inc., a global biotechnology company. Evolocumab received FDA approval in August 2015 for hyperlipidaemia and HoFH, with cardiovascular outcomes indication added in 2017 following the FOURIER trial. A.K. Pharma supplies only genuine Repatha sourced from authorized Amgen distributors.
Related Heart Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Repatha used for? Repatha (Evolocumab) is used to lower LDL cholesterol in patients with primary hyperlipidaemia, familial hypercholesterolaemia, and established cardiovascular disease — and to reduce the risk of heart attack, stroke, and coronary revascularisation. More information available at MedlinePlus.
Q. What is the generic name of Repatha? The generic name of Repatha is Evolocumab. It is a fully human anti-PCSK9 monoclonal antibody belonging to the PCSK9 inhibitor class of cholesterol-lowering medicines.
Q. How much does Repatha lower LDL cholesterol? Repatha reduces LDL-C by 50-60% on top of maximally tolerated statin therapy — enabling most patients to achieve guideline-recommended LDL-C targets of <55 mg/dL for very high cardiovascular risk.
Q. Is Repatha available in India? Repatha can be supplied to hospitals, cardiology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. What is the difference between Repatha and Sybrava? Both inhibit PCSK9 and reduce LDL-C by 50-60%. Repatha is a monoclonal antibody injected every 2 weeks or monthly while Sybrava (Inclisiran) is an siRNA that silences PCSK9 production — injected only twice yearly after initiation. Both have proven cardiovascular outcomes benefits.
Q. What is the price of Repatha in India? Repatha price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Repatha from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Repatha in bulk? Yes. A.K. Pharma supplies Repatha in bulk to hospitals, cardiology centres, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Why Order Repatha from A.K. Pharma?
Contact A.K. Pharma for Repatha Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
